Genocea Biosciences Inc. buy Heureka
Summary
This prediction ended on 16.03.20 with a price of €1.36. The prediction for Genocea Biosciences Inc. disappointed with a performance of -14.47%. Heureka has 50% into this predictionGenocea Biosciences (Symbol GNCA) (WKN A2PK76) is a publicly traded, clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel vaccines and immunotherapies for various infectious diseases and cancer. With a unique approach to unlocking the power of T-cells in rapid vaccine and immunotherapy discovery, the company has established a robust pipeline targeting a wide spectrum of viral, bacterial, and parasitic diseases as well as oncology indications. Notable programs include GEN-003 for genital herpes and GEN-009, an innovative and personalized neoantigen cancer vaccine. Listed on the Nasdaq stock exchange, Genocea is dedicated to improving patient outcomes through cutting-edge research, expertise in immune targeting, and a strong commitment to scientific innovation.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Genocea Biosciences Inc. | - | - | - | - |
iShares Core DAX® | 3.523% | 3.763% | 26.705% | 22.165% |
iShares Nasdaq 100 | 1.026% | 2.380% | 29.587% | 39.491% |
iShares Nikkei 225® | -0.063% | 0.000% | 15.214% | 2.291% |
iShares S&P 500 | 0.557% | 2.222% | 27.662% | 40.483% |
Comments by Heureka for this prediction
In the thread Genocea Biosciences Inc. diskutieren
In the thread Trading Genocea Biosciences Inc.